Newsletter | June 5, 2023

06.05.23 -- Overcoming Characterization And Budget Constraints To Address Poor Solubility

Oral Delivery Potential For Macromolecules: Parallel Screening Approach

Salmon calcitonin is a peptide with poor oral bioavailability. To assess its potential for oral delivery, a parallel screening was conducted with two different technologies targeting duodenal and sublingual biological barriers respectively. Examine the study data and how the optimal formulation and dose form was identified.

Bioavailability Enhancement Through Spray-Dried Dispersions

Very few new molecular entities in active clinical development are readily bioavailable, and when dosed at escalated levels, even these may not be sufficiently absorbed. Spray-dried amorphous dispersion is rising in popularity due to its enhanced solubility and advanced control. Learn how amorphous dispersion might help better your formulation.

Improved Bioavailability In 12 Weeks

A company developing treatments for unmet medical needs was developing a lead compound that showed clinical promise but had limited bioavailability owing to low solubility. Explore the formulation challenges, including the molecular characterization and limited budget, and the structured three-step approach that helped improve the treatment's solubility.

Designing Complex Release Oral Solids

The World Health Organization indicates that only about 50% of patients with chronic diseases living in developed countries follow treatment recommendations. Discover how controlled and modified release treatments can provide improved compliance and therapeutic effectiveness with the right release profile based on API properties, PK challenges, and patient needs.